Sarah Cannon, the Cancer Institute of HCA Healthcare, offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. Sarah Cannon’s cancer programs include individualized patient navigation provided by oncology-trained nurses, ~1,200 stem cell transplants performed annually throughout the Sarah Cannon Transplant and Cellular Therapy Network, hundreds of clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing world-class cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit sarahcannon.com.
Lung Cancer: Co-Chaired by David Spigel, MD and Melissa L. Johnson, MD
December 3rd 2020Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of lung cancer.
Gastrointestinal Malignancies: Chaired by Johanna Bendell, MD
November 17th 2020Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of gastrointestinal cancers.
Trastuzumab Deruxtecan, Tucatinib Generate Excitement in Metastatic HER2+ Breast Cancer
August 27th 2020Erika P. Hamilton, MD, discusses the pivotal data that led to the approvals of trastuzumab deruxtecan and tucatinib in metastatic HER2-positive breast cancer, factors considered in terms of treatment selection, and emerging agents under exploration.
Dr. Yardley on Endocrine Therapy Plus CDK4/6 Inhibitors in Breast Cancer With Visceral Metastases
August 17th 2020Denise Yardley, MD, discusses the role of endocrine therapy in combination with CDK4/6 inhibitors in patients with hormone receptor–positive, HER2-negative breast cancer and visceral metastases.
Dr. Burris and Dr. Graff Talk COVID-19 and Cancer Care, Telemedicine, and ASCO Initiatives
May 25th 2020Howard A. "Skip" Burris, III, MD, FASCO, FACP, and Stephanie L. Graff, MD, discuss how the COVID-19 pandemic has affected cancer care, the collaborative efforts made between Sarah Cannon Research Institute and HCA to increase access to investigational COVID-19 treatments, and the steps ASCO has taken to ensure its members’ professional education and well-being during this time.